NCT02655822 2021-08-30Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced CancersCorvus Pharmaceuticals, Inc.Phase 1 Completed502 enrolled